Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idecabtagene vicleucel plus lenalidomide maintenance versus lenalidomide maintenance alone after ASCT in newly diagnosed multiple myeloma with suboptimal response
2022-501346-30-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Sep 2023
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Idecabtagene vicleucel plus lenalidomide maintenance with Lenalidomide maintenance alone (2 arms). Primary endpoint: Progression-free survival. Planned start Sep 2023; status: authorised.
02
Drugs
idecabtagene vicleucellenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-501346-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501346-30-00.